Canaccord Genuity Reiterates Buy on Passage Bio, Maintains $14 Price Target
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Whitney Ijem reiterates a Buy rating on Passage Bio (NASDAQ:PASG) and maintains a $14 price target.
March 05, 2024 | 2:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Canaccord Genuity analyst Whitney Ijem reiterates a Buy rating on Passage Bio and maintains a $14 price target.
The reiteration of a Buy rating and maintenance of a $14 price target by a reputable analyst like Whitney Ijem from Canaccord Genuity is likely to instill confidence among investors and could positively influence the stock price of Passage Bio in the short term. The specific mention of the price target provides a clear benchmark for expectations.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100